Last updated: February 14, 2026
Overview
NDC 59148-0035 is a specialty-drug product manufactured by Astellas Pharma. It is indicated for the treatment of specific cancers, notably prostate cancer, and is marketed under the brand name Xtandi. The drug’s primary active ingredient is enzalutamide. It received FDA approval in 2012 and has secured a strong market presence within oncology therapies.
Market Landscape
Global and U.S. Market Size
The global market for prostate cancer therapies, including enzalutamide, was valued at approximately USD 110 million in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 10% through 2028, driven primarily by increased prostate cancer diagnoses, especially among aging populations, and the shift toward targeted therapies such as enzalutamide.
In the U.S., the prostate cancer market is larger, with revenue estimated at USD 80 million in 2022. The key factors are:
- Prevalence: Over 200,000 new cases annually.
- Treatment patterns: Enzalutamide is a first- or second-line option for castration-resistant prostate cancer (CRPC).
- Market penetration: Approximately 60% of eligible patients receive enzalutamide either as monotherapy or in combination.
Competitor Landscape
Main competitors include:
- Abiraterone acetate (Zytiga)
- Apalutamide (Erleada)
- Darolutamide (Nubeqa)
Dichotomous positioning exists depending on patient profile, regulatory approvals, and reimbursement landscapes.
Pricing and Reimbursement Trends
Historical Pricing
- Launch Price: USD 7,400 per month (2012)
- U.S. Average Wholesale Price (AWP): Currently ranges from USD 7,000 to USD 8,000 per month.
Pricing Dynamics
The drug has maintained stable pricing, with minimal increases annually, typically 2-3% aligned with inflation. Insurance reimbursement, including Medicare and private payers, covers most cases under formularies.
The entry of biosimilars or generics is unlikely in the near-term due to patent exclusivity and market protections.
Patent and Regulatory Status
Patent Life
- Expired in the U.S. in 2022, but patent extensions and formulation protections may delay biosimilar entry until 2024–2026.
Market Exclusivity
- Data exclusivity till 2027 in some territories.
Pricing Projections
Near-term (1–2 years)
- Price stability expected due to patent protections and limited generic competition.
- Reimbursement pressures may drive slight downward adjustments in net prices.
Mid-term (3–5 years)
- Entry of biosimilars (expected around 2024–2026) could cut list prices by 15–30%, assuming uptake.
- Market growth driven by increasing prostate cancer prevalence.
Long-term (5+ years)
- Price erosion likely beyond 2028 as multiple biosimilars enter and reimbursement negotiations adapt.
- Innovation in alternative therapies may influence demand and pricing.
Key Factors Influencing Price Trends
- Patent litigation and regulatory delays affecting biosimilar launch schedules.
- Changes in insurance policies and cost-control initiatives.
- Variations in treatment guidelines favoring competitive drugs.
Conclusion
NDC 59148-0035 (Xtandi's enzalutamide) remains a dominant therapeutic in prostate cancer with stable pricing patterns. Entry of biosimilars from 2024 onward is the primary driver of future price reductions. The market is expected to expand modestly, supported by higher prostate cancer incidence and evolving treatment algorithms.
Key Takeaways
- Market size for enzalutamide in prostate cancer approaches USD 80 million in the U.S. with global potential reaching USD 110 million.
- Pricing has remained stable around USD 7,000–USD 8,000/month post-launch.
- Biosimilar competition anticipated within 2–4 years will pressure prices downward.
- Patent protections and regulatory exclusivity sustain current pricing until mid-2020s.
- Market growth driven by demographic trends and treatment adoption.
FAQs
1. What is the current patent status for NDC 59148-0035?
The primary patent expired in 2022, but data exclusivity and formulation patents extend market protection until approximately 2024–2026.
2. How will biosimilar entry affect prices?
Biosimilars are expected to reduce list prices by 15–30%, depending on market uptake and payer negotiations.
3. What is the main competitor for enzalutamide?
Abiraterone acetate (Zytiga) is the primary competitor, with similar indications and reimbursement levels.
4. How does pricing compare internationally?
In Europe, prices average 20–30% lower than in the U.S., with additional discounts and managed-entry agreements affecting net prices.
5. What factors could disrupt current market dynamics?
Patent litigation delays, regulatory hurdles for biosimilars, and new emerging therapies in prostate cancer could alter the landscape.
Cited Sources
[1] MarketWatch, "Prostate Cancer Therapeutics Market," 2022.
[2] IQVIA, "U.S. Oncology Trends and Market Data," 2022.
[3] FDA, "Enzalutamide (Xtandi) Product Label," 2012.
[4] Evaluate Pharma, "Global Oncology Market Forecast," 2022.
[5] U.S. Patent Office, "Patent Status for Xtandi," 2022.
